Mycobacterium Avium Complex, Nontuberculous Mycobacterial Lung Disease
Conditions
Brief summary
The SALINE trial will investigate the effect of Hypertonic Saline inhalation plus best supportive care on burden of symptoms, clearance of mycobacteria and functional capacities in participants with Mycobacterium avium complex lung disease and compare the effect to treatment with best supportive care alone.
Detailed description
The treatment of Mycobacterium avium complex (MAC) lung disease consists of best supportive care, often accompanied by long-lasting multi-drug antibiotic regimens. Two major radiologic patterns exist: nodular-bronchiectatic and fibrocavitary disease, characterized by slow and rapid progression of disease, respectively. SALINE is an open-label, randomized, two-arm controlled study that investigates the effect of Hypertonic Saline inhalation (HSi) plus best supportive care versus best supportive care alone for 12 weeks in participants with nodular-bronchiectatic MAC lung disease. The investigators hypothesize that HSi added to best supportive care will improve health-related quality of life and reduce mycobacterial load more than best supportive care alone Participants will be randomized 1:1 to a study arm. Best supportive care comprises of management of a predisposing (lung) condition, guidance in smoking cessation, respiratory physiotherapy (e.g. airway clearance) and nutritional guidance. HSi will be administered two times daily. Antibacterial therapy against other bacterial infections and inhaled corticosteroids are allowed during the study period.
Interventions
DEVICEHypertonic Saline inhalation
Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
Sponsors
Radboud University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* International guideline criteria for nodular-bronchiectatic MAC lung disease, i.e. symptomatic, nodular bronchiectatic lesions seen on thorax radiography and ≥2 positive cultures of the same MAC species or one positive culture from a bronchoalveolar lavage; * ≥1 positive MAC sputum cultures must be collected in the previous 4 months; * Signed and dated patient informed consent.
Exclusion criteria
* Fibrocavitary MAC lung disease; * Antimycobacterial treatment in the last 6 months; * Previous MAC lung disease treatment failure, defined as persistent culture positivity despite \>6 months of guideline-recommended treatment; * Current clinical relevant asthma or otherwise bronchial hyperresponsiveness that is judged to be a contra-indication for HSi. * Current HSi use * Former adverse reaction to HSi (note: former HSi use that was stopped due to a lack of clinical improvement is not an exclusion criterium); * Hypertonic saline intolerability during the screening test inhalation * Diagnosis of HIV; * Diagnosis of Cystic fibrosis (CF); * Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period; * Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment * Current use of chronic systemic corticosteroids at doses of 15 mg/day for more than 3 months * Prior lung or other solid organ transplant * Known or suspected current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in health-related quality of life | 12 weeks | Measured by the Quality of Life - Bronchiectasis (QOL-B) with NTM module questionnaire at baseline, after 4, 8 and 12 weeks. The QOL-B asks the participant to subjectively rank their symptoms using a 4 scale base ranging from "a lot of difficulty" to "no difficulty", "always" to "never", "completely true" to "not at all true" and "a lot" to "not at all" for 8 domains: physical/role/emotional/social functioning, vitality, treatment burden, health perception and respiratory symptoms. The NTM-module also asks participants to subjectively rank eating problems, body image, digestive symptoms, and NTM symptoms on a 4 scale base. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sputum culture conversion | 12 weeks | A conversion from positive sputum cultures at baseline to negative sputum cultures after study treatment, defined by two or more negative sputum cultures sampled a week apart. |
| Change in semi-quantitative culture results | 12 weeks | Change in acid fast bacilli (AFB) smear determined by auramine staining |
| (Serious) Adverse Events as assessed by CTCAE v5.0 | 12 weeks | Number and severity of (serious) Adverse Events as assessed by CTCAE |
| Treatment failure | 12 weeks | Progression of disease that requires the start of antimycobacterial treatment as per the treating physician's discretion. |
| Change in pulmonary function parameters | 12 weeks | Forced expiratory volume in 1 second (FEV1; L), Forced Vital Capacity (FVC; L), Inspiratory Capacity (IC; L), Functional Residual Volume (FRC; L) and Total Lung Capacity (TLC; L). |
| Change in physical function capacity | 12 weeks | Change in 6-Minute Walking Distance (6MWD). |
| Change in inflammatory serum biomarkers | 12 weeks | Change in C-reactive protein (CRP). |
| Therapy adherence | 12 weeks | Self-reported therapy adherence expressed as percentage taken of total HSi administrations. |
| Change in self-reported health status | 12 weeks | Change in the Nijmegen Clinical Screening Instrument (NCSI) from baseline to 12 weeks. The NCSI evaluates clinical, social and emotional self-reported measures, serves as a tool for an individualized treatment plan and can be repeated regularly to monitor the treatment effect |
Countries
Netherlands
Contacts
CONTACTArthur Lemson, MSc
CONTACTWouter Hoefsloot, MSc, PhD
Outcome results
None listed